IPP Bureau
Bayer’s Nubeqa receives EU approval for patients with advanced prostate cancer
By IPP Bureau - July 21, 2025
European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Biogen to invest $2 billion to expand manufacturing capability in North Carolina
By IPP Bureau - July 21, 2025
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
Bristol Myers Squibb announces topline Results from Phase 3 Independence trial for Reblozyl
By IPP Bureau - July 19, 2025
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Vimta Labs Q1 FY26 PAT climbs to Rs. 18.89 Cr
By IPP Bureau - July 18, 2025
Vimta Labs has reported total income of Rs. 99.31 crores during the period ended June 30, 2025
Zigly launches its first pet hospital in Mumbai
By IPP Bureau - July 18, 2025
The new Zigly center features and offers comprehensive veterinary services
Kenvue collaborates with API to launch India’s first cough clinics
By IPP Bureau - July 18, 2025
Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough
Brenntag Specialties Pharma offering phosphate-based excipients by Budenheim
By IPP Bureau - July 18, 2025
Phosphate-based excipients provide higher bulk densities and enable the reduction of the tablet sizes
Lupin receives Form 483 with 4 observations from USFDA for Pithampur unit-2
By IPP Bureau - July 18, 2025
The company is addressing these observations comprehensively
Concord Biotech announces successful completion EU GMP inspection at its API facility
By IPP Bureau - July 18, 2025
This achievement underscores our unwavering commitment to upholding the highest standards of quality, safety, and regulatory compliance
Shilpa Medicare receives EIR from USFDA for Unit VI, Bengaluru
By IPP Bureau - July 17, 2025
This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms
SMS Lifesciences India receives EIR with VAI status from USFDA for API facility at Kazipally
By IPP Bureau - July 17, 2025
The receipt of EIR reaffirms the company's commitment to maintaining global quality standards
Lupin launches Loteprednol Etabonate ophthalmic suspension 0.5% in US
By IPP Bureau - July 17, 2025
Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroidresponsive inflammatory conditions of the palpebral and bulbar conjunctiva
Suven Life Sciences announces first patient randomized in Phase-2b clinical trial of Ropanicant
By IPP Bureau - July 17, 2025
There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
